Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Jun 29, 2015
Numerous studies have shown that patients who receive early palliative experience greater physical health and quality of life—and that these benefits extend to patients’ families as well. Studies have also shown that palliative care, which includes the management of symptoms such as pain, nausea, and anxiety; psychosocial counseling; and...
Jun 22, 2015
For years now, researchers have been turning the neat, legible, type-written notes within electronic health records (EHRs) to uncover a treasure-trove of patient data...
Jun 15, 2015
“ . . . if you’re deciding who to test for mutations based on family history, you’re going to miss a lot of people who are carriers.”
Jun 08, 2015
A new JCO study found that smokers recently diagnosed with cancer were significantly more likely to quit smoking than smokers who had not been diagnosed with cancer. 
May 30, 2015
Watch an exclusive video of Dr. Peter Yu delivering his Presidential Address at the 51st Annual Meeting of the American Society of Clinical Oncology.
May 18, 2015
Numerous studies have shown that children treated for acute lymphoblastic leukemia (ALL) experience increased rates of cognitive deficits in terms of attention span, working memory, and processing complex information.
May 11, 2015
Several clinical trials have shown that for women with ovarian cancer, IP chemotherapy–which allows the drugs to be delivered directly into the peritoneum at a 20- to 1000-fold greater concentration than IV chemotherapy—confers survival advantages.
May 04, 2015
During the past two decades, there has been an increase in the number of long-term survivors of autologous and allogeneic hematopoietic stem-cell transplantations (HSCT).
Apr 27, 2015
For women with metastatic or recurrent cervical cancer, paclitaxel plus carboplatin confers the same survival advantage as paclitaxel plus cisplatin, currently the standard of care (overall survival [OS] was 17.5 months in the carboplatin group versus 18.3 months in the cisplatin group)...
Apr 13, 2015
The study found that among the 35% of patients who expressed a strong desire for genetic testing, 196 (43.4%) did not have a relevant discussion...

Pages